44 results about "Desmopressin" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

An apparatus and method for transdermally delivering desmopressin comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the desmopressin is contained in a biocompatible coating that is applied to the microprojection member.

The present invention relates to a stable aqueous composition comprising desmopressin or its other pharmaceutically acceptable salts in a pharmaceutically acceptable carrier, wherein the carrier comprises a buffering agent, a parahydroxybenzoate preservative, and a cosolvent.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1,000 μm. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

The present invention relates to a novel method for the preparation of a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, comprising providing a desmopressin containing granulate suitable for compression to a pharmaceutically acceptable tablet, as well as to solid dosage forms, preferably tablets, obtainable by said method.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1,000 mum. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient. It addresses means for providing increased shelf-life for said active ingredient in said dosage form.

The present invention relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, and to say solid dosage form. In one embodiment it specifically relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent and / or carrier, wherein said solid dosage form is adapted to prevent moisture related degradation of said desmopressin.

A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma / serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma / serum to about 10.0 picogram desmopressin per mL plasma / serum. Articles of manufacture and methods of using the above invention are also disclosed.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The invention relates to a method for solid cyclizing synthesis of desmopressin. The method solves the technical problem that the existing air liquid-phase oxidation method produces a large amount of waste liquid, utilizes behindhand processes, has low efficiency and produces more by-products because of oxidation adopting iodine as an oxidizing agent. The method comprises the following steps of orderly coupling nine amino acids to a RinkAmideAm resin, wherein the coupled amino acids orderly comprise Fmoc-Gly-OH, Fmoc-D-Arg(pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH and Mpa(Trt)-OH, removing protective groups Trt on Cys(Trt) and Mpa(Trt) by TFA / DCM having content of 1%, carrying out solid cyclizing synthesis by an oxidation reagent to obtain a cyclopeptide resin and carrying out cracking to obtain desmopressin. The invention provides the method for solid cyclizing synthesis of desmopressin and the method has simple processes, a low cost and a high yield and is suitable for large-scale production.

An eco-wood formulation finds new uses as construction materials. A rigid polymer material sheet for use in building construction comprises a polymer mixture of ultrafine particles of polyvinylchloride (PVC) impact modifier, plant fiber, coupling agent, smoke suppressant, activated clay, lubricant, an activator, environmentally friendly flame retardant, heat stabilizers, odorless crosslinking agent, foaming agent, desmopressin agent. Alternatively, the rigid polymer material sheet is composed of: a polymer mixture of PVC, plasticizer, nitrile rubber, PCC, stearate, zinc oxide, retardant heat, heat stabilizers, crosslinking agent, vesicant; whereby said rigid polymer material sheet provides enhanced thermal resistance and sound attenuation properties for use in building construction, aviation and marine industries.

A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.

The present invention relates to a novel and improved process for the preparation of 1-deamino-8-D-arginine vasopressin (Desmopressin) or its pharmaceutically acceptable salts thereof and also relates to an improved process for the purification of Desmopressin or its pharmaceutically acceptable salts. Further, the present invention also relates to pharmaceutical composition of Desmopressin or its pharmaceutically acceptable salts thereof.

The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma / serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma / serum to about 10.0 picogram desmopressin per mL plasma / serum. Articles of manufacture and methods of using the above invention are also disclosed.

The invention provides a synthesis method of desmopressin. The method comprises the following steps: coupling amino acid monomers and Mpa onto a solid carrier, from which the protective groups have been moved, in a water solution according to a sequence of PG-Gly-OH, PG-D-Arg-OH, PG-Pro-OH, PG-Cys(Trt)-OH, PG-Asn-OH, PG-Gln-OH, PG-Phe-OH, PG-Tyr-OH, and Mpa, wherein the PG represents a water-soluble amino protective group, oxidizing, cracking, and purifying. The provided synthesis method does not use any organic solvent, the cost is saved, the environment is protected, moreover, part of the side-chain functional groups in the peptide sequence does not need to be protected, the operation is simple, the cost is low, the yield is high, and thus the provided synthesis method can generate considerable economic benefits, is very practical, and has a wide application prospect.

A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition has a non-adrenaline and NET inhibitor for noradrenaline. The NET inhibitor may be cocaine or an analogue thereof or a tricyclic antidepressant. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The ratio between the NET inhibitor and nor-adrenaline is about 1:1. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial pressure of about 60 mmHg. The composition may be infused by a pump at a rate of about 1.7 ml / hour decreasing dose-dependent to about 0.4 ml / hour after 24 hours.

A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and / or preservation. The fluid includes cocaine or a stimulating analogue thereof; nor-adrenalin; and / or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenalin; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

Use of factor XIII for treating von Willebrand's disease. A patient having von Willebrand's disease is treated by administering factor XIII generally in conjunction with factor VIII concentrate, 1-desamino-8-D-arginine vasopressin (DDAVP) or desmopressin.

The present disclosure relates generally to pharmaceutical compositions comprising an active ingredient and a stabilizing agent, wherein the active ingredient is desmopressin or a pharmaceutically acceptable salt thereof, and wherein the stabilizing agent is one or more gums. The present disclosure further relates to methods of increasing the stability of a pharmaceutical composition comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient; methods for preparing orally disintegrating films comprising desmopressin or a pharmaceutically acceptable salt thereof and orally disintegrating films prepared thereby; and methods of treating or preventing nocturnal enuresis or nocturnal polyuria by administering stabilized pharmaceutical compositions comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient.

The invention discloses a synthetic method of desmopressin. The synthetic method comprises the following steps: 1) selecting solid phase carrier resin; 2) synthesizing main chain peptide resin; 3) conducting cracking to remove resin and protective groups; and 4) conducting liquid phase electrochemical oxidation and coupling disulfide bonds to obtain the desmopressin. According to the method, the problem of specific selectivity of reaction can be avoided, the utilization rate of fragment peptide resin, the utilization rate of main chain fragments and the atom utilization rate can be increased,so that the production cost is reduced, the use of chemical oxidants iodine and hydrogen peroxide is avoided, and the method is more environment-friendly and more conforms to the concept of green chemistry.

The invention is related to a pharmaceutical composition comprising an active ingredient and a stabilizing agent, wherein the active ingredient is desmopressin or a pharmaceutical acceptable salt thereof, and the stabilizing agent is at least one gum. The invention relates to uses of one or more gums to increase the stability of a pharmaceutical composition comprising desmopressin or a pharmaceutical acceptable salt thereof as an active ingredient against denaturation, a method for preparing an orally disintegrating film comprising desmopressin or a pharmaceutically acceptable salt thereof as well as the orally disintegrating film obtainable thereby.

The invention relates to a medical composition containing 0.5-20 microgrammes of desmopressin and a pharmaceutically acceptable carrier. The invention further relates to a medical composition containing desmopressin the pharmaceutically acceptable carrier, wherein the medical composition can effectively establish stable blood plasma / blood serum desmopressin concentration from 0.1 micromicrograms of desmopressin / mL blood plasma / blood serum to 10.0 micromicrograms of desmopressin / mL blood plasma / blood serum. The invention further discloses a product made from the medical composition and the preparation method of the product.

The present invention relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, and to said solid dosage form. In one embodiment it specifically relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent and / or carrier, wherein said solid dosage form is adapted to prevent moisture related degradation of said desmopressin.